Acceleron Pharma - XLRN Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $179.88
  • Forecasted Upside: 0.63 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 9 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
+0 (0.00%)
Get New Acceleron Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XLRN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XLRN

Analyst Price Target is $179.88
▲ +0.63% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Acceleron Pharma in the last 3 months. The average price target is $179.88, with a high forecast of $180.00 and a low forecast of $179.00. The average price target represents a 0.63% upside from the last price of $178.75.

This chart shows the closing price for XLRN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 9 investment analysts is to hold stock in Acceleron Pharma. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 9 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 9 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 10 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 10 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 9 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 9 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 9 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 9 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/6/2021Jefferies Financial GroupInitiated CoverageHold$180.00Low
10/4/2021Raymond JamesDowngradeStrong-Buy ➝ Market PerformLow
10/1/2021Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$180.00Low
10/1/2021BarclaysDowngradeOverweight ➝ Equal Weight$150.00 ➝ $180.00Low
9/30/2021CowenDowngradeOutperform ➝ Market Perform$173.00 ➝ $180.00Low
9/30/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$180.00Low
9/30/2021HC WainwrightDowngradeBuy ➝ Neutral$168.00 ➝ $180.00High
9/30/2021Piper SandlerDowngradeOverweight ➝ Neutral$146.00 ➝ $180.00High
9/30/2021SVB LeerinkBoost TargetMarket Perform$148.00 ➝ $180.00High
9/27/2021Royal Bank of CanadaBoost TargetSector Perform$113.00 ➝ $179.00High
8/5/2021Piper SandlerBoost TargetOverweight$143.00 ➝ $146.00Medium
7/19/2021Wolfe ResearchInitiated CoverageBuy$183.00Medium
6/27/2021SVB LeerinkReiterated RatingHoldLow
6/24/2021OppenheimerBoost TargetOutperform$141.00 ➝ $160.00Medium
6/15/2021SVB LeerinkReiterated RatingHoldHigh
3/29/2021The Goldman Sachs GroupReiterated RatingNeutral$132.00High
3/29/2021SVB LeerinkReiterated RatingOutperform ➝ Market Perform$148.00N/A
3/23/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$148.00High
3/22/2021The Goldman Sachs GroupReiterated RatingNeutral$132.00 ➝ $132.00N/A
3/11/2021Wolfe ResearchInitiated CoverageOutperform$200.00Medium
3/1/2021CitigroupBoost TargetBuy$137.00 ➝ $171.00Low
2/26/2021Piper SandlerBoost TargetOverweight$130.00 ➝ $143.00Low
2/26/2021Morgan StanleyBoost TargetOverweight$135.00 ➝ $145.00High
2/26/2021SVB LeerinkBoost TargetOutperform$138.00 ➝ $148.00Low
1/29/2021JPMorgan Chase & Co.Boost TargetOverweight$133.00 ➝ $153.00Low
1/19/2021Raymond JamesBoost TargetStrong-Buy$155.00 ➝ $160.00High
1/19/2021HC WainwrightBoost TargetBuy$148.00 ➝ $168.00High
12/21/2020BarclaysBoost TargetOverweight$133.00 ➝ $150.00Medium
12/16/2020Morgan StanleyBoost TargetOverweight$130.00 ➝ $135.00Low
11/16/2020OppenheimerBoost TargetOutperform$120.00 ➝ $131.00Low
11/6/2020Morgan StanleyBoost TargetOverweight$125.00 ➝ $130.00High
11/6/2020SVB LeerinkBoost TargetOutperform$134.00 ➝ $138.00High
11/6/2020HC WainwrightBoost TargetBuy$137.00 ➝ $148.00High
10/13/2020Morgan StanleyBoost TargetOverweight$123.00 ➝ $125.00Low
9/29/2020HC WainwrightReiterated RatingBuyLow
8/24/2020Raymond JamesInitiated CoverageStrong-Buy$155.00Medium
8/7/2020Credit Suisse GroupBoost TargetOutperform$134.00 ➝ $135.00High
8/7/2020SVB LeerinkBoost TargetOutperform$132.00 ➝ $134.00High
7/15/2020Morgan StanleyBoost TargetOverweight$122.00 ➝ $123.00Low
7/7/2020Piper SandlerLower TargetOverweight$135.00 ➝ $130.00Low
6/26/2020SVB LeerinkBoost TargetOutperform$127.00 ➝ $132.00High
6/25/2020CowenBoost TargetOutperform$121.00 ➝ $140.00High
6/25/2020Royal Bank of CanadaBoost TargetSector Perform$72.00 ➝ $99.00High
6/25/2020Credit Suisse GroupBoost TargetOutperform$123.00 ➝ $134.00Medium
6/25/2020OppenheimerReiterated RatingBuy$115.00 ➝ $120.00High
6/2/2020CitigroupBoost TargetBuy$136.00 ➝ $137.00High
5/12/2020SVB LeerinkBoost Target$104.00 ➝ $127.00High
5/12/2020BarclaysReiterated RatingBuy$116.00High
5/12/2020JPMorgan Chase & Co.Boost TargetOverweight$108.00 ➝ $118.00High
5/12/2020OppenheimerBoost TargetOutperform$112.00 ➝ $115.00High
5/8/2020Credit Suisse GroupBoost TargetOutperform$99.00 ➝ $123.00Low
5/4/2020HC WainwrightReiterated RatingBuy$137.00High
4/6/2020Piper SandlerReiterated RatingBuy$135.00Medium
4/6/2020Credit Suisse GroupReiterated RatingBuy$99.00Medium
4/6/2020OppenheimerBoost TargetOutperform$108.00 ➝ $112.00Low
4/6/2020HC WainwrightBoost TargetBuy$128.00 ➝ $137.00Medium
4/6/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell$73.00High
3/10/2020HC WainwrightLower TargetBuy$129.00 ➝ $128.00High
3/2/2020CitigroupLower TargetBuy$138.00 ➝ $136.00Low
2/27/2020BarclaysInitiated CoverageOverweight$107.00Medium
2/18/2020HC WainwrightBoost TargetBuy$90.00 ➝ $129.00Low
2/11/2020OppenheimerBoost TargetOutperform$79.00 ➝ $112.00Medium
2/3/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$52.00 ➝ $122.00Low
1/28/2020OppenheimerBoost Target$57.00 ➝ $79.00High
1/28/2020CowenBoost Target$78.00 ➝ $109.00High
1/28/2020Piper SandlerBoost TargetOverweight$73.00 ➝ $135.00High
1/28/2020The Goldman Sachs GroupReiterated RatingNeutral$47.00 ➝ $81.00High
1/28/2020Royal Bank of CanadaBoost TargetSector Perform$72.00High
1/28/2020Credit Suisse GroupBoost TargetOutperform ➝ Outperform$58.00 ➝ $99.00High
1/28/2020CitigroupBoost TargetBuy ➝ Buy$75.00 ➝ $138.00High
1/27/2020Royal Bank of CanadaReiterated RatingHold$47.00Medium
1/22/2020CitigroupBoost TargetBuy$52.00 ➝ $75.00High
12/17/2019Morgan StanleyBoost TargetEqual Weight$48.00 ➝ $52.00High
12/10/2019HC WainwrightInitiated CoverageBuy$88.00Low
11/11/2019HC WainwrightReiterated RatingBuy$68.00 ➝ $88.00Medium
11/6/2019CowenReiterated RatingBuyLow
10/21/2019Piper Jaffray CompaniesSet TargetBuy$71.00Low
10/13/2019CowenReiterated RatingBuyMedium
10/11/2019Morgan StanleyLower TargetEqual Weight$52.00 ➝ $48.00Low
9/17/2019SVB LeerinkDropped CoverageBuy$55.00N/A
9/17/2019OppenheimerSet TargetBuy$58.00Low
9/17/2019HC WainwrightReiterated RatingBuy$68.00High
9/17/2019CitigroupLower TargetBuy ➝ Buy$61.00 ➝ $52.00High
9/6/2019HC WainwrightReiterated RatingBuy$69.00Medium
8/26/2019Credit Suisse GroupSet TargetBuy$58.00Low
8/6/2019JPMorgan Chase & Co.Lower TargetOverweight$61.00 ➝ $58.00Medium
7/15/2019Morgan StanleySet TargetHold$53.00Medium
6/4/2019HC WainwrightReiterated RatingBuy$69.00High
5/29/2019The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$54.00 ➝ $54.00Medium
5/24/2019CitigroupReiterated RatingBuy ➝ Buy$66.00Low
5/13/2019HC WainwrightBoost TargetBuy$66.00 ➝ $69.00High
5/12/2019CowenReiterated RatingBuy$78.00High
5/10/2019Piper Jaffray CompaniesReiterated RatingOverweight$71.00 ➝ $74.00Low
5/3/2019BarclaysDowngradeOverweight ➝ Equal Weight$54.00 ➝ $45.00Medium
4/22/2019CIBCReiterated RatingOutperform ➝ OutperformLow
4/22/2019OppenheimerReiterated RatingOutperformLow
2/28/2019HC WainwrightReiterated RatingBuy ➝ Buy$72.00 ➝ $67.00High
2/25/2019CowenInitiated CoverageOutperform$78.00High
12/3/2018HC WainwrightReiterated RatingBuy$72.00Low
9/17/2018Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$52.00 ➝ $75.00High
9/10/2018Morgan StanleyInitiated CoverageEqual Weight ➝ Equal Weight$55.00Medium
8/3/2018HC WainwrightReiterated RatingBuy$73.00Medium
7/23/2018HC WainwrightReiterated RatingBuy$74.00Medium
7/13/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$50.00Low
7/12/2018Royal Bank of CanadaReiterated RatingHold$48.00Medium
7/10/2018HC WainwrightBoost TargetBuy$74.00High
7/10/2018UBS GroupBoost TargetBuy$62.00High
7/10/2018Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$32.00High
6/29/2018Credit Suisse GroupBoost TargetPositive ➝ Outperform$55.00 ➝ $60.00High
6/29/2018Piper Jaffray CompaniesBoost TargetOverweight$55.00High
6/29/2018The Goldman Sachs GroupUpgradeSell ➝ Neutral$21.00 ➝ $40.00High
5/9/2018Credit Suisse GroupSet TargetBuy$55.00High
5/9/2018HC WainwrightBoost TargetBuy$69.00Low
4/26/2018HC WainwrightReiterated RatingBuy$62.00Medium
3/2/2018Credit Suisse GroupReiterated RatingBuy$55.00High
3/1/2018CitigroupBoost TargetBuy ➝ Positive$44.00 ➝ $63.00High
2/28/2018BarclaysBoost TargetOverweight ➝ Overweight$50.00 ➝ $54.00High
2/28/2018HC WainwrightReiterated RatingBuy$62.00High
2/28/2018Piper Jaffray CompaniesBoost TargetOverweight$53.00High
2/26/2018JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$33.00High
1/18/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$55.00Medium
1/8/2018OppenheimerReiterated RatingHoldMedium
12/11/2017OppenheimerReiterated RatingHoldMedium
12/11/2017HC WainwrightReiterated RatingBuy$62.00Medium
11/14/2017OppenheimerReiterated RatingHoldN/A
11/14/2017Credit Suisse GroupSet TargetBuy$35.00 ➝ $51.00N/A
11/7/2017HC WainwrightBoost TargetBuy ➝ Buy$57.00 ➝ $62.00N/A
11/2/2017Royal Bank of CanadaReiterated RatingHoldN/A
10/12/2017HC WainwrightInitiated CoverageBuy ➝ Buy$57.00N/A
9/20/2017OppenheimerReiterated RatingHoldHigh
9/20/2017BarclaysBoost TargetOverweight$42.00 ➝ $50.00High
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$44.00Low
9/12/2017UBS GroupReiterated RatingBuy$36.00 ➝ $50.00High
9/5/2017OppenheimerReiterated RatingHoldLow
(Data available from 8/19/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.


  • No negative mentions tracked during this time.


  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Acceleron Pharma logo
Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $178.75
Low: $178.75
High: $178.75

50 Day Range

MA: $176.25
Low: $172.08
High: $179.68

52 Week Range

Now: $178.75
Low: $108.82
High: $189.99



Average Volume

572,759 shs

Market Capitalization

$10.93 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Acceleron Pharma?

The following Wall Street sell-side analysts have issued stock ratings on Acceleron Pharma in the last year: Barclays PLC, Cowen Inc, HC Wainwright, Jefferies Financial Group Inc., Morgan Stanley, Piper Sandler, Raymond James, Royal Bank of Canada,, and SVB Leerink LLC.
View the latest analyst ratings for XLRN.

What is the current price target for Acceleron Pharma?

8 Wall Street analysts have set twelve-month price targets for Acceleron Pharma in the last year. Their average twelve-month price target is $179.88, suggesting a possible upside of 0.6%. Barclays PLC has the highest price target set, predicting XLRN will reach $180.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $179.00 for Acceleron Pharma in the next year.
View the latest price targets for XLRN.

What is the current consensus analyst rating for Acceleron Pharma?

Acceleron Pharma currently has 9 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in XLRN, but not buy more shares or sell existing shares.
View the latest ratings for XLRN.

What other companies compete with Acceleron Pharma?

Other companies that are similar to Acceleron Pharma include Qiagen, Neurocrine Biosciences, Repligen, Bio-Techne and Exelixis. Learn More about companies similar to Acceleron Pharma.

How do I contact Acceleron Pharma's investor relations team?

Acceleron Pharma's physical mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company's listed phone number is (617) 649-9200 and its investor relations email address is [email protected] The official website for Acceleron Pharma is Learn More about contacing Acceleron Pharma investor relations.